Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:04 PM
Ignite Modification Date:
2025-12-24 @ 3:04 PM
NCT ID:
NCT02478359
Eligibility Criteria:
Inclusion Criteria:
* Patients with any COPD-related hospitalization, emergency department visit or observational stay in the previous 12 months are eligible for the study. COPD-related encounters are defined according to the Centers for Medicare and Medicaid Services (CMS) and National Quality Forum (NQF) criteria for the Hospital Readmission Reduction Program. The following principal discharge diagnoses of COPD (ICD-9 codes: 491.21, 491.22, 491.8, 491.9, 492.8, 493.20, 493.21, 493.22, and 496) or respiratory failure (ICD-9 codes: 518.81, 518.82, 518.84, 799.1) with a secondary diagnosis of COPD exacerbation (ICD-9 codes: 491.21, 491.22, 493.21, 493.22) will be used
* Age \>40 years
* On at least a bronchodilator or steroid inhaler prior to the encounter or if not on an inhaler, had a previous COPD diagnosis
* Continuous health plan membership in the 12 months prior to the encounter
Exclusion Criteria:
* FEV1/FVC ratio \>0.70 at any point in the past year for those with spirometry data
* Discharged to hospice, a skilled nursing facility, long term-care or another acute care hospital during the index admission
* Level of function at admission or discharge during the index admission is bed bound
* Has Alzheimers disease, dementia or metastatic cancer
* Morbidly obese (BMI \>40)
* Completed pulmonary rehabilitation in the last 6 months
* Deceased
* Dis-enrolled from the health plan
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
41 Years
Study:
NCT02478359
Study Brief:
Protocol Section:
NCT02478359